A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

NCT05075564 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: Part 1 ES002023
DRUG: Part 2 ES002023

Sponsor

Elpiscience Biopharma, Ltd.